Peptide Compounding in 2026: What Pharmacy Owners Should Know About Professional Liability and Risk

Peptide Compounding in 2026: What Pharmacy Owners Should Know About Professional Liability and Risk

Peptide therapy has become one of the more talked-about areas of healthcare in recent years. As patient interest has grown, so has interest among prescribers, wellness clinics, compounding pharmacies, and other healthcare businesses.

For independent pharmacy owners, though, I think the conversation needs to go beyond whether peptide therapy is growing.

There are some important questions to ask:

What peptides is your pharmacy actually compounding? Does your professional liability carrier know you're doing it? And do you understand how your coverage would respond if something goes wrong?

Those questions have become even more relevant in 2026.

In July, the FDA's Pharmacy Compounding Advisory Committee considered several peptide-related bulk drug substances for possible inclusion on the Section 503A Bulks List, including BPC-157, KPV, TB-500, MOTS-C, emideltide (DSIP), Semax and Epitalon.

That doesn't mean all of those substances suddenly became approved for use in compounded medications. An FDA advisory committee provides recommendations and scientific advice; its recommendations are not themselves final FDA decisions.

For pharmacy owners, that's an important distinction.

But from my perspective as someone who works with pharmacies on insurance and risk management, there's another issue that deserves attention:

Your pharmacy's operations may be changing faster than your insurance program. That is why pharmacy professional liability coverage should be reviewed against the operations you have today, not just the operations described at the last renewal.

Peptide Compounding Isn't Just a Regulatory Question

When a pharmacy begins compounding something new, it's easy to think primarily about the clinical and regulatory requirements.

Those obviously matter.

But there's also an insurance question.

The professional liability policy protecting your pharmacy was underwritten based on information the carrier received about your operations.

What types of prescriptions do you fill?

Do you compound?

Do you perform sterile compounding?

What percentage of your revenue comes from compounding?

What substances are you working with?

Who are your patients?

How are your compounded products distributed?

Those details can influence how an insurance company evaluates the risk.

That's why one of the first questions I would ask a pharmacy owner involved with peptide compounding is remarkably simple:

Does your professional liability carrier know what you're doing?

I wouldn't automatically assume peptide compounding is covered.

I also wouldn't automatically assume it's excluded.

I'd want to look at the actual policy, the application and the pharmacy's current operations and make sure they still line up.

Start With What You're Actually Compounding

"Peptides" is a broad description.

From an insurance standpoint, saying that a pharmacy "does peptide compounding" doesn't tell me nearly enough.

I'd want to know exactly what the pharmacy is compounding and how.

The FDA maintains different requirements for bulk drug substances used in compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

For a state-licensed pharmacy operating under Section 503A, FDA says bulk drug substances generally must meet one of several conditions: comply with an applicable USP or NF monograph, be a component of an FDA-approved drug product when an applicable monograph doesn't exist, or appear on the 503A Bulks List when the other conditions don't apply. FDA also maintains an interim policy while it evaluates certain nominated substances.

The rules are different for 503B outsourcing facilities.

That's one reason pharmacy owners should be careful about headlines suggesting that a particular peptide has been "approved."

FDA approval of a drug, consideration of a bulk substance for the 503A Bulks List, and an advisory committee recommendation are not interchangeable concepts.

If there's uncertainty about whether a particular substance can legally be compounded in a particular situation, that's a regulatory question that should be addressed with appropriate pharmacy counsel or regulatory expertise.

From the insurance side, however, I want the carrier to understand what the pharmacy is actually doing.

Don't Overlook the Source of the Ingredient

There's another risk-management issue that I've written about recently: where your ingredients come from.

FDA specifically encourages compounders to know their bulk drug substance supplier. For 503A compounding, bulk substances must also be accompanied by a valid certificate of analysis and manufactured by an establishment registered with FDA under Section 510.

That isn't just paperwork.

When you're putting a substance into a compounded medication that ultimately reaches a patient, supplier quality becomes part of the pharmacy's risk.

A pharmacy can have excellent internal procedures and still face a serious problem if an ingredient entering the compounding process isn't what the pharmacy expected it to be.

That makes supplier qualification, documentation and traceability important parts of risk management.

If something does happen, the ability to determine:

• what ingredient was used • where it came from • which lot was involved • when it was received • which preparations contained it • which patients received those preparations

can become extremely important.

Peptides Can Present Unique Safety Questions

FDA has specifically identified safety concerns with certain bulk drug substances used in compounding, including several peptide-related substances.

Those concerns vary by substance. FDA has discussed issues including immunogenicity, peptide-related impurities, aggregation, limited human safety data and difficulties characterizing certain peptides.

That doesn't mean every peptide presents the same risk.

It means pharmacies shouldn't treat "peptides" as one uniform category.

For example, during the July 2026 advisory committee process, FDA's evaluation of BPC-157-related bulk substances concluded that the criteria weighed against placement on the 503A Bulks List. Among FDA's stated concerns were limited safety information, potential immunogenicity risks and insufficient evidence regarding effectiveness for the use evaluated.

That's precisely why I think pharmacy owners need to stay current rather than relying on what was permissible, common or understood a year or two ago.

One Compounding Problem Can Become Multiple Claims

This is one of the most important insurance issues for any compounding pharmacy. I have also covered the broader professional-liability considerations for compounding pharmacies.

Imagine that a pharmacy compounds one preparation using a particular ingredient lot.

That preparation isn't dispensed to one patient.

It's dispensed to 20.

If something is wrong with that preparation and several patients are injured, the pharmacy may not be dealing with one isolated dispensing error anymore.

It could be dealing with multiple injured patients arising from the same underlying event.

That's when the structure of a professional liability policy becomes extremely important.

Pharmacy owners should understand concepts such as:

Per-claim limits. How much protection is available for an individual covered claim?

Aggregate limits. How much is available across covered claims during the policy period?

Related-claims provisions. Could multiple claims arising from the same batch, ingredient, process or event be treated as related under the policy?

Defense costs. Are legal-defense expenses inside or outside the liability limits?

These aren't questions you want to investigate for the first time after several patients have already retained attorneys.

Don't Forget About the Pharmacy License

Patient injury isn't the only potential consequence of a compounding problem.

There could also be a Board of Pharmacy investigation or other regulatory proceeding.

And there are potentially two different license exposures involved:

The pharmacy's license and the pharmacist's individual license.

Those aren't necessarily the same exposure, and pharmacy owners shouldn't automatically assume the same protection applies to both.

When I review professional liability coverage with pharmacy owners, license defense is one of the areas I pay particularly close attention to.

How much is available?

Who qualifies for protection?

Does the policy protect the pharmacy license, individual pharmacists, or both?

Are defense expenses subject to a separate sublimit?

Does that limit get shared among multiple proceedings?

The answers depend on the actual policy.

A large professional liability limit on the declarations page doesn't necessarily tell you how much protection exists for a licensing investigation.

Sterile Compounding Deserves Additional Attention

If the peptide is being prepared as a sterile injectable, the risk profile changes again.

Now you're not only thinking about whether the ingredient itself is appropriate.

You're also dealing with the risks inherent in sterile compounding: contamination, sterility assurance, potency, preparation procedures, storage, handling and other quality-control considerations.

The potential severity of an error can also increase when a preparation is administered by injection.

From an insurance standpoint, I would want the pharmacy's sterile compounding operations clearly disclosed and accurately represented to the carrier.

If a pharmacy started with relatively simple nonsterile compounding several years ago but has since expanded into sterile preparations and peptide therapies, that's exactly the type of operational evolution that should trigger an insurance review.

Your Insurance Application Is a Snapshot in Time

This may be the biggest takeaway.

Insurance policies often renew annually.

Pharmacies don't necessarily change on that same schedule.

A pharmacy might add sterile compounding.

Start providing vaccinations.

Expand delivery.

Begin working with a new prescriber network.

Add a specialty program.

Increase compounding substantially.

Or begin compounding substances it had never previously handled.

Meanwhile, the insurance policy keeps renewing.

That's how gaps between what the carrier thinks the pharmacy does and what the pharmacy actually does can develop.

I don't think pharmacy owners should wait until renewal to ask whether a major operational change affects their insurance.

When the business changes materially, the insurance conversation should follow.

Questions I'd Ask If My Pharmacy Were Compounding Peptides

If I owned an independent pharmacy involved in peptide compounding, these are some of the questions I'd want answered:

1. Exactly which peptides are we compounding?

2. Are we operating under the appropriate federal and state compounding requirements for those substances?

3. Where are our bulk ingredients coming from, and what supplier-verification procedures do we have?

4. Does our professional liability carrier know we're compounding these substances?

5. Does our insurance application accurately describe our current compounding operations?

6. Are there exclusions, limitations or conditions in our policy that could affect coverage?

7. What are our per-claim and aggregate professional liability limits?

8. How does our policy address multiple or related claims arising from the same preparation, batch or event?

9. How much license-defense coverage do we have for the pharmacy and for individual pharmacists?

10. If we're performing sterile compounding, has that operation been specifically disclosed and properly underwritten?

Those are questions worth answering before there's a claim.

Risk Management Comes Before Insurance

Insurance shouldn't be the first line of defense here.

Good compounding practices, appropriate regulatory compliance, supplier due diligence, documentation, quality controls, staff training and strong procedures are what reduce the likelihood of an incident occurring in the first place.

Insurance is the financial backstop when those systems don't prevent a loss.

And peptide compounding is an area where pharmacy owners should be particularly careful about assuming yesterday's answer is still today's answer.

The regulatory environment continues to develop. FDA continues to evaluate bulk drug substances, and its compounding policies and lists continue to evolve.

Your pharmacy may be evolving too.

Your insurance program needs to keep up.

The Bottom Line

Peptide therapy may represent an opportunity for some independent pharmacies, but opportunity and risk often arrive together.

From an insurance perspective, the question isn't simply:

"Does my policy cover peptides?"

A better conversation is:

"What exactly are we compounding, does our carrier understand the operation, and how would our professional liability coverage respond if a patient were injured or our license were challenged?"

Those questions are much easier to answer before something happens.

And that's really the point of good risk management.

If you own an independent pharmacy and your compounding operations have changed, it may be worth reviewing whether your current professional liability program still reflects what you actually do.

This article is intended for general educational purposes and is not legal, regulatory, medical or insurance coverage advice. Compounding requirements and insurance coverage depend on the specific circumstances, applicable law and regulations, and the terms, conditions and exclusions of the individual insurance policy.